Salem Billan
AuthID: R-007-2XB
1
TÃTULO: An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck Full Text
AUTORES: Vassiliki Saloura; Ezra E W Cohen; Lisa Licitra; Salem Billan; Jose Dinis; Steen Lisby; Thomas C Gauler;
PUBLICAÇÃO: 2014, FONTE: CANCER CHEMOTHERAPY AND PHARMACOLOGY, VOLUME: 73, NÚMERO: 6
AUTORES: Vassiliki Saloura; Ezra E W Cohen; Lisa Licitra; Salem Billan; Jose Dinis; Steen Lisby; Thomas C Gauler;
PUBLICAÇÃO: 2014, FONTE: CANCER CHEMOTHERAPY AND PHARMACOLOGY, VOLUME: 73, NÚMERO: 6
2
TÃTULO: An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
AUTORES: Vassiliki Saloura; Ezra E W Cohen; Lisa F Licitra; Salem Billan; Jose Dinis; Steen Lisby; Thomas Christoph Gauler;
PUBLICAÇÃO: 2013, FONTE: 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 31, NÚMERO: 15
AUTORES: Vassiliki Saloura; Ezra E W Cohen; Lisa F Licitra; Salem Billan; Jose Dinis; Steen Lisby; Thomas Christoph Gauler;
PUBLICAÇÃO: 2013, FONTE: 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 31, NÚMERO: 15
INDEXADO EM: 
WOS
WOS